MedTrace Logo

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

NCT03322657 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2021-11-16

Study results available
· View outcomes & findings →

Summary

The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other half will receive Sugammadex.

Conditions

  • Neuromuscular Blockade
  • Anesthesia

Interventions

DRUG

Neostigmine

Neostigmine injection

DRUG

Glycopyrrolate

Glycopyrrolate injection

DRUG

Sugammadex

Sugammadex injection

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2020-12-31
Completion
2021-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322657 on ClinicalTrials.gov